EULAR definition of difficult-to-treat rheumatoid arthritis

  • G. Nagy
  • , N.M. Roodenrijs
  • , P.M. Welsing
  • , M. Kedves
  • , A. Hamar
  • , M.C. van der Goes
  • , A. Kent
  • , M. Bakkers
  • , E. Blaas
  • , L. Senolt
  • , Z. Szekanecz
  • , E. Choy
  • , M. Dougados
  • , J.W. Jacobs
  • , R. Geenen
  • , H.W. Bijlsma
  • , A. Zink
  • , D. Aletaha
  • , L. Schoneveld
  • , P. van Riel
  • L. Gutermann, Y. Prior, E. Nikiphorou, G. Ferraccioli, G. Schett, K.L. Hyrich, U. Mueller-Ladner, M.H. Buch, I.B. McInnes, D. van der Heijde, J.M. van Laar

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

BACKGROUND: Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be considered to have 'difficult-to-treat RA'. However, uniform terminology and an appropriate definition are lacking.

OBJECTIVE: The Task Force in charge of the "Development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis" aims to create recommendations for this underserved patient group. Herein, we present the definition of difficult-to-treat RA, as the first step.

METHODS: The Steering Committee drafted a definition with suggested terminology based on an international survey among rheumatologists. This was discussed and amended by the Task Force, including rheumatologists, nurses, health professionals and patients, at a face-to-face meeting until sufficient agreement was reached (assessed through voting).

RESULTS: The following three criteria were agreed by all Task Force members as mandatory elements of the definition of difficult-to-treat RA: (1) Treatment according to European League Against Rheumatism (EULAR) recommendation and failure of ≥2 biological disease-modifying antirheumatic drugs (DMARDs)/targeted synthetic DMARDs (with different mechanisms of action) after failing conventional synthetic DMARD therapy (unless contraindicated); (2) presence of at least one of the following: at least moderate disease activity; signs and/or symptoms suggestive of active disease; inability to taper glucocorticoid treatment; rapid radiographic progression; RA symptoms that are causing a reduction in quality of life; and (3) the management of signs and/or symptoms is perceived as problematic by the rheumatologist and/or the patient.

CONCLUSIONS: The proposed EULAR definition for difficult-to-treat RA can be used in clinical practice, clinical trials and can form a basis for future research.

Original languageEnglish
Pages (from-to)31-35
Number of pages5
JournalAnnals of the Rheumatic Diseases
Volume80
Issue number1
DOIs
Publication statusPublished - Jan 2021

Bibliographical note

Funding Information:
This study was funded by European League Against Rheumatism.

Publisher Copyright:
© Author(s) (or their.

Keywords

  • arthritis
  • immune system diseases
  • rheumatoid
  • synovitis

Fingerprint

Dive into the research topics of 'EULAR definition of difficult-to-treat rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this